Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857372 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
A Phase 1 study of Mesothelioma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
- 16
- Study locations
NCT04857372: Active Phase 1 study of Mesothelioma, sponsored by Novartis Pharmaceuticals.
NCT04857372 is a Phase 1 study of Mesothelioma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 137 participants, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (30% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04857372, a Phase 1 study of Mesothelioma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Primary Outcome
Safety and tolerability of IAG933
Conditions Studied
Interventions
- DRUG IAG933
Study Locations (16)
Other
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Zurich
- Novartis Investigative Site - Manchester
MI
- Novartis Investigative Site - Milan
- Novartis Investigative Site - Rozzano
California
- University of California LA - Los Angeles
Illinois
- Uni of Chi Medi Ctr Hema and Onco - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Victoria
- Novartis Investigative Site - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2026-09-04 |
| Phase | Phase 1 |
What the registry record for NCT04857372 still lists
NCT04857372 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which IAG933 is the first listed.
NCT04857372 lists 16 locations in 12 states (Other, MI, California).
Frequently Asked Questions
What is clinical trial NCT04857372 about?
NCT04857372 is a clinical study titled "A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors". The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
What is the current status of trial NCT04857372?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2021-10-21. Estimated completion is 2026-09-04.
What conditions does trial NCT04857372 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT04857372?
The interventions under investigation include: IAG933 (DRUG).
Who is sponsoring clinical trial NCT04857372?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04857372 being conducted?
This trial has 16 study locations across California, Illinois, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04857372's enrollment target sits among peer trials
137 19th of 46 higher than 28 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RECRUITING · Phase 1
-
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
RECRUITING · Phase 1
-
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RECRUITING · Phase 1
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI